Genetic studies on the role of proteinases and growth factors in atherosclerosis and aneurysm formation

Annals of the New York Academy of Sciences

Volumn 947, Issue , 2001, Pages 124-133

  Luttun, A ^a   Carmeliet, P ^a   Clowes, A ^a   Berk, B ^a   Steinberg, D ^a   Numano, F ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Aneurysm formation; Atherosclerosis; Genetic studies; Growth factors; Proteinases

Indexed keywords

GROWTH FACTOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE;

ANEURYSM; ATHEROGENESIS; ATHEROSCLEROSIS; CONFERENCE PAPER; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; NONHUMAN;

EID: 0035686841     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03935.x     Document Type: Conference Paper

References (53)

1. Molecular bases of the acute coronary syndromes
2. The pathogenesis of atherosclerosis: A perspective for the 1990s
3. Mouse models of atherosclerosis
4. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells
5. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
6. Changes in arterial expression of fibrinolytic system proteins in atherogenesis
7. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis
8. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery
9. Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1
10. Viewpoint: Are studies in genetically altered mice out of control?
11. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study
12. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
13. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system
14. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris
15. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
16. Matrix metalloproteinases and cardiovascular disease
17. Metalloproteinases and their inhibitors in matrix remodeling
18. Plasminogen activators and matrix metalloproteinases in angiogenesis
19. Matrix metalloproteinases and their inhibitors
20. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site
21. Matrix metalloproteinases in abdominal aortic aneurysm: Characterization, purification, and their possible sources
22. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion
23. Polymorphism in matrix metalloproteinase gene promoters: Implication in regulation of gene expression and susceptibility of various diseases
24. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis
25. Size matters: The relationship between MMP-9 expression and aortic diameter
26. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms
27. Enhanced expression of matrix metalloproteinase-9 in abdominal aortic aneurysms
28. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: A circulating marker of degenerative aneurysm disease
29. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study
30. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms
31. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm
32. Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms. Relation to size and rupture
33. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms
34. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model
35. Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury
36. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms
37. Proteinases in cardiovascular aneurysms and rupture: Targets for therapy?
38. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade
39. Genes specifically expressed at growth arrest of mammalian cells
40. Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation
41. New insights into the control of cell growth; the role of the AxI family
42. Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3
43. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl Sky, and Mer receptor tyrosine kinases
44. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6
45. Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: Contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells
46. GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells
47. Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein-coupled receptor agonists in rats
48. Prevention of growth arrest-induced cell death of vascular smooth muscle cells by a product of growth arrest-specific gene, gas6
49. Expression of receptor tyrosine kinase Axl and its ligand Gas6 in rheumatoid arthritis: Evidence for a novel endothelial cell survival pathway
50. A product of growth arrest-specific gene 6 modulates scavenger receptor expression in human vascular smooth muscle cells
51. GAS6 mediates adhesion of cells expressing the receptor tyrosine kinase Axl
52. GAS6 inhibits granulocyte adhesion to endothelial cells
53. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis